lodoxamide ethyl has been researched along with Chronic Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gonzalez-Gonzalez, JM; Macias-Rodriguez, Y; Rodriguez-Garcia, A | 1 |
| Bloch-Michel, E; Denis, D; Di Giovanni, A; Helleboid, L; Lecorvec, M; Sebastiani, A; Tazartes, M; Verin, P | 1 |
1 trial(s) available for lodoxamide ethyl and Chronic Disease
| Article | Year |
|---|---|
Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Child, Preschool; Chronic Disease; Conjunctivitis, Allergic; Dipeptides; Double-Blind Method; Female; Humans; Male; Middle Aged; Oxamic Acid; Patient Satisfaction; Treatment Outcome | 1998 |
1 other study(ies) available for lodoxamide ethyl and Chronic Disease
| Article | Year |
|---|---|
Efficacy and safety of 0.1% lodoxamide for the long-term treatment of superior limbic keratoconjunctivitis.
Topics: Administration, Topical; Adult; Aged; Anti-Allergic Agents; Chronic Disease; Conjunctiva; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Keratoconjunctivitis; Limbus Corneae; Middle Aged; Ophthalmic Solutions; Oxamic Acid; Prospective Studies; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2018 |